Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Piper Sandler Downgrades Intra-Cellular Therapies to Neutral, Raises Price Target to $132

Author: Benzinga Newsdesk | January 14, 2025 11:37am
Piper Sandler analyst David Amsellem downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Overweight to Neutral and raises the price target from $107 to $132.

Posted In: ITCI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist